Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Respiration; International Review of Thoracic Diseases
Eva BrunnemerMichael Kreuter

Abstract

Nintedanib, an oral tyrosine kinase inhibitor, has been shown to slow down the progression of idiopathic pulmonary fibrosis (IPF) in two randomised placebo-controlled trials by reducing the annual decline in forced vital capacity (FVC). However, real-world experience is limited. To assess the efficacy and safety of nintedanib in a large cohort of patients treated at a tertiary referral site for interstitial lung diseases. The records of patients with a confirmed diagnosis of IPF were reviewed. Full medical history, pulmonary function, and adverse events (AEs) were recorded from each clinic visit. Disease progression was defined as a reduction in FVC ≥5% and/or in diffusing capacity of the lung for carbon monoxide ≥15% according to recent publications. Only patients with a treatment duration ≥3 months were included in the efficacy evaluation. A total of 64 patients were treated. Mean ± standard deviation (SD) FVC was 71 ± 21% predicted, and the mean time from diagnosis to initiation of nintedanib treatment was 23.8 months. Nearly half of patients (n = 30, 47%) had received prior pirfenidone treatment. The mean duration of follow-up was 11 months. At 6 months following initiation of nintedanib, 67% of the patients were stable. Th...Continue Reading

References

Jun 23, 2007·American Journal of Respiratory and Critical Care Medicine·Harold R CollardUNKNOWN Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators
Apr 8, 2011·American Journal of Respiratory and Critical Care Medicine·Ganesh RaghuUNKNOWN ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis
Sep 24, 2011·American Journal of Respiratory and Critical Care Medicine·Roland M du BoisAthol U Wells
Oct 14, 2011·The New England Journal of Medicine·Luca RicheldiRoland M du Bois
Jul 3, 2013·Drug Design, Development and Therapy·Hannah V WoodcockToby M Maher
May 20, 2014·The New England Journal of Medicine·Luca RicheldiUNKNOWN INPULSIS Trial Investigators
Aug 15, 2014·Respiration; International Review of Thoracic Diseases·Ute OltmannsMichael Kreuter
Mar 15, 2015·Therapeutics and Clinical Risk Management·Argyris TzouvelekisPaolo Spagnolo
Jul 16, 2015·American Journal of Respiratory and Critical Care Medicine·Ganesh RaghuUNKNOWN Latin American Thoracic Association
Sep 24, 2015·American Journal of Respiratory and Critical Care Medicine·Ulrich CostabelArata Azuma
Apr 7, 2016·The Lancet. Respiratory Medicine·Michael KreuterUlrich Costabel
Apr 23, 2016·The European Respiratory Journal·Michael KreuterToby M Maher
Aug 6, 2016·Respiratory Medicine·Andriana I PapaioannouSpyridon A Papiris
Aug 22, 2016·Respiration; International Review of Thoracic Diseases·Francesco BonellaUNKNOWN German Nintedanib Compassionate Use Consortium
Oct 22, 2016·Medizinische Klinik, Intensivmedizin und Notfallmedizin·R CsernusC P Heußel
Mar 28, 2017·Respiration; International Review of Thoracic Diseases·Manuela Funke-ChambourRomain Lazor

❮ Previous
Next ❯

Citations

Aug 8, 2018·Journal of Clinical Medicine·Shaney L BarrattNazia Chaudhuri
Sep 27, 2018·Therapeutic Advances in Respiratory Disease·Pilar Rivera-OrtegaNazia Chaudhuri
Nov 18, 2018·The European Respiratory Journal·Luca RicheldiToby M Maher
Sep 19, 2019·Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia·Carlos Alberto de Castro PereiraMarcelo Fouad Rabahi
Mar 3, 2020·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Kohei Togami
Sep 22, 2019·Journal of Clinical Medicine·Elisabetta BalestroPaolo Spagnolo
Jan 8, 2020·Respiratory Research·Claudia ValenzuelaMichael Kreuter
Jun 4, 2020·American Journal of Physiology. Lung Cellular and Molecular Physiology·Yael AschnerGregory P Downey
Oct 21, 2018·Respiratory Research·Hee-Young YoonJin Woo Song
Jun 24, 2020·Annals of the American Thoracic Society·Margaret L SalisburyUNKNOWN IPF-PRO Registry principal investigators as follows
Jan 6, 2021·International Journal of Molecular Sciences·Grzegorz GrześkAlicja Nowaczyk
Feb 24, 2021·British Journal of Clinical Pharmacology·Pietro AmeriItalo Porto
Mar 29, 2021·Pharmacology & Therapeutics·Gang LiuPhilip M Hansbro
Apr 22, 2021·Expert Opinion on Drug Safety·Giacomo SgallaLuca Richeldi
May 25, 2021·Clinics in Chest Medicine·Erica Farrand, Andrew H Limper
Nov 20, 2018·Respiration; International Review of Thoracic Diseases·Sabina A Guler, Manuela Funke-Chambour
Dec 14, 2018·Respiration; International Review of Thoracic Diseases·Elisabeth BendstrupMarlies Wijsenbeek

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.